New Zealand markets closed

BIIB Apr 2022 295.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
60.800.00 (0.00%)
As of 02:52PM EST. Market open.
Full screen
Previous close60.80
Open60.80
Bid0.00
Ask0.00
Strike295.00
Expiry date2022-04-14
Day's range60.80 - 60.80
Contract rangeN/A
Volume1
Open interest7
  • Bloomberg

    Biogen Sells Bioepis Stake for $2.3 Billion to Samsung Biologics

    (Bloomberg) -- Samsung Biologics Co. will buy 49.9% of Samsung Bioepis from Biogen Inc., according to a regulatory filing, giving the South Korean drugmaker full ownership of the joint venture. Most Read from BloombergApple to Rival Square by Turning iPhones Into Payment TerminalsStocks Drop in Roller-Coaster Ride for Wall Street: Markets WrapCrypto Secrecy Makes DeFi a Financial Felon’s WonderlandHow a Fox News Interview Threw the Antiwork Subreddit Into ChaosAmericans’ Gas Stoves Are as Bad fo

  • GlobeNewswire

    Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion

    The companies will continue with their exclusive agreements, including for commercialization of their current portfolioCAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that they have entered into an agreement whereby Samsung Biologics will acquire Biogen’s equity stake in the Samsung Bioepis joint venture for an aggregate consideration of up to USD $2.3 billion.Biogen and Samsung Bioepis have built the industry leading anti-TNF portfolio in Europe1.

  • Zacks

    Earnings Preview: Biogen Inc. (BIIB) Q4 Earnings Expected to Decline

    Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.